Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
TA

NASDAQ · TARS

Tarsus Pharmaceuticals, Inc. Common Stock

Healthcare · Biotechnology

$81.12

Down-$1.65 (-1.99%)

Updated Sep 11, 2026, 4:59 AM

SID Score

6.2/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.47B
P/E ratio
-42.92
Dividend yield
0.00%
52-week range
$53.89 – $91.53
Volume
403.28K
Avg. volume
558K

Price performance

TARS price history

1M range · 20 trading sessions · Daily adjusted prices

TARS closed at $81.12 after 20 trading sessions, up 17.77% for the selected period.

Last close
$81.12
Period change
+17.77%
Period low
$68.88
Period high
$90.78
Daily close
View OHLC price history
TARS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$80.892$83.34$80.81$81.12403.28K
Sep 9, 2026$86.31$87.31$82.67$82.77565.45K
Sep 8, 2026$89.67$90.75$87.01$87.221.82M
Sep 4, 2026$82.70$91.53$81.07$90.781.6M
Sep 3, 2026$82.76$84.50$81.9454$83.205733.75K
Sep 2, 2026$74.63$82.97$74.105$82.761.9M
Sep 1, 2026$73.86$75.08$73.515$74.05587.27K
Aug 31, 2026$71.47$74.935$70.71$74.24711.97K
Aug 28, 2026$71.19$72.03$70.73$71.76615.74K
Aug 27, 2026$70.07$72.145$69.465$71.92876.93K
Aug 26, 2026$71.10$71.15$69.77$70.65611.55K
Aug 25, 2026$72.55$74.00$71.05$71.45538.35K
Aug 24, 2026$72.88$73.08$71.765$72.81414.07K
Aug 21, 2026$71.72$73.135$71.26$72.70636.34K
Aug 20, 2026$72.81$73.42$70.0975$71.49538.09K
Aug 19, 2026$72.00$73.51$71.37$73.44757.5K
Aug 18, 2026$70.73$71.50$69.665$71.03628.83K
Aug 17, 2026$68.83$70.78$68.71$70.615541.18K
Aug 14, 2026$68.82$69.70$67.61$69.20448.26K
Aug 13, 2026$70.72$71.345$68.06$68.88631.79K

Latest TARS news

The latest Smart Investors Daily articles mentioning TARS.

Stock researchCompany · Overview

TARS research

Overview

Company profile and research snapshot.

Company profile

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$84.75
Implied upside
—
Analysts
—
TARS recent ratings
DateFirmRatingTarget
Sep 8, 2026JefferiesBuy—
Aug 12, 2026OppenheimerOutperform—
Jul 31, 2026MizuhoOutperform—
Jul 21, 2026GuggenheimBuy—
Jul 9, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a potentially blinding disease with no FDA-approved therapy Strengthens Tarsus’ differentiated pipeline and leadership in eye care IRVINE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it has completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a privately hel

Yahoo · Sep 1, 2026

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8thH.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15th, where management plans to participate in a fireside chat at 6:00 a.m. PT / 9:00 a.m. ET. Live webcasts and additional information can be accessed on the ev

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By